Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs

Dik J. Kwekkeboom, Jan Mueller-Brand, Giovanni Paganelli, Lowell B. Anthony, Stanislas Pauwels, Larry K. Kvols, Thomas M. O'Dorisio, Roelf Valkema, Lisa Bodei, Marco Chinol, Helmut R. Maecke, Eric P. Krenning

Research output: Contribution to journalArticle

330 Citations (Scopus)

Abstract

A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of radiolabeled somatostatin analogs. Initial studies with high doses of [111In- diethylenetriaminepentaacetic acid (DTPA)0]octreotide in patients with metastasized neuroendocrine tumors were encouraging, although partial remissions were uncommon. Another radiolabeled somatostatin analog that is used for peptide receptor radionuclide therapy (PRRT) is [90Y-1,4,7,10- tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) 0,Tyr3]octreotide. Various phase 1 and phase 2 PRRT trials have been performed with this compound. Despite differences in the protocols used, complete and partial remissions in most of the studies with [ 90Y-DOTA0, Tyr3]octreotide were in the same ranges, 10%-30%; these ranges were higher than those obtained with [ 111In-DTPA0]octreotide. Treatment with the newest radiolabeled somatostatin analog, [177Lu-DOTA0,Tyr 3]octreotate, which has a higher affinity for the subtype 2 somatostatin receptor, resulted in complete or partial remissions in 30% of 76 patients. Tumor regression was positively correlated with a high level of uptake on OctreoScan imaging, a limited hepatic tumor mass, and a high Karnofsky performance score. Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all 111In-, 90Y-, or 177Lu-labeled somatostatin analogs that have been used for PRRT. The results obtained with [ 90Y-DOTA0,Tyr3]-octreotide and [ 177Lu-DOTA0,Tyr3]octreotate are very encouraging in terms of tumor regression. Also, if kidney protective agents are used, the side effects of this therapy are few and mild, and the duration of the therapy response for both radiopharmaceuticals is more than 2 y. These data compare favorably with those for the limited number of alternative treatment approaches.

Original languageEnglish
JournalJournal of Nuclear Medicine
Volume46
Issue number1 SUPPL.
Publication statusPublished - Jan 1 2005

Fingerprint

Peptide Receptors
Somatostatin
Radioisotopes
Octreotide
Therapeutics
Neuroendocrine Tumors
Neoplasms
Protective Agents
Radiopharmaceuticals
Kidney
Acids
Liver

Keywords

  • Gastroenteropancreatic tumors
  • Radionuclide therapy
  • Somatostatin
  • Somatostatin receptor

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Kwekkeboom, D. J., Mueller-Brand, J., Paganelli, G., Anthony, L. B., Pauwels, S., Kvols, L. K., ... Krenning, E. P. (2005). Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. Journal of Nuclear Medicine, 46(1 SUPPL.).

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. / Kwekkeboom, Dik J.; Mueller-Brand, Jan; Paganelli, Giovanni; Anthony, Lowell B.; Pauwels, Stanislas; Kvols, Larry K.; O'Dorisio, Thomas M.; Valkema, Roelf; Bodei, Lisa; Chinol, Marco; Maecke, Helmut R.; Krenning, Eric P.

In: Journal of Nuclear Medicine, Vol. 46, No. 1 SUPPL., 01.01.2005.

Research output: Contribution to journalArticle

Kwekkeboom, DJ, Mueller-Brand, J, Paganelli, G, Anthony, LB, Pauwels, S, Kvols, LK, O'Dorisio, TM, Valkema, R, Bodei, L, Chinol, M, Maecke, HR & Krenning, EP 2005, 'Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs', Journal of Nuclear Medicine, vol. 46, no. 1 SUPPL..
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. Journal of Nuclear Medicine. 2005 Jan 1;46(1 SUPPL.).
Kwekkeboom, Dik J. ; Mueller-Brand, Jan ; Paganelli, Giovanni ; Anthony, Lowell B. ; Pauwels, Stanislas ; Kvols, Larry K. ; O'Dorisio, Thomas M. ; Valkema, Roelf ; Bodei, Lisa ; Chinol, Marco ; Maecke, Helmut R. ; Krenning, Eric P. / Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. In: Journal of Nuclear Medicine. 2005 ; Vol. 46, No. 1 SUPPL.
@article{f521f28e9d694a27934e3146f95e0256,
title = "Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs",
abstract = "A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of radiolabeled somatostatin analogs. Initial studies with high doses of [111In- diethylenetriaminepentaacetic acid (DTPA)0]octreotide in patients with metastasized neuroendocrine tumors were encouraging, although partial remissions were uncommon. Another radiolabeled somatostatin analog that is used for peptide receptor radionuclide therapy (PRRT) is [90Y-1,4,7,10- tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) 0,Tyr3]octreotide. Various phase 1 and phase 2 PRRT trials have been performed with this compound. Despite differences in the protocols used, complete and partial remissions in most of the studies with [ 90Y-DOTA0, Tyr3]octreotide were in the same ranges, 10{\%}-30{\%}; these ranges were higher than those obtained with [ 111In-DTPA0]octreotide. Treatment with the newest radiolabeled somatostatin analog, [177Lu-DOTA0,Tyr 3]octreotate, which has a higher affinity for the subtype 2 somatostatin receptor, resulted in complete or partial remissions in 30{\%} of 76 patients. Tumor regression was positively correlated with a high level of uptake on OctreoScan imaging, a limited hepatic tumor mass, and a high Karnofsky performance score. Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all 111In-, 90Y-, or 177Lu-labeled somatostatin analogs that have been used for PRRT. The results obtained with [ 90Y-DOTA0,Tyr3]-octreotide and [ 177Lu-DOTA0,Tyr3]octreotate are very encouraging in terms of tumor regression. Also, if kidney protective agents are used, the side effects of this therapy are few and mild, and the duration of the therapy response for both radiopharmaceuticals is more than 2 y. These data compare favorably with those for the limited number of alternative treatment approaches.",
keywords = "Gastroenteropancreatic tumors, Radionuclide therapy, Somatostatin, Somatostatin receptor",
author = "Kwekkeboom, {Dik J.} and Jan Mueller-Brand and Giovanni Paganelli and Anthony, {Lowell B.} and Stanislas Pauwels and Kvols, {Larry K.} and O'Dorisio, {Thomas M.} and Roelf Valkema and Lisa Bodei and Marco Chinol and Maecke, {Helmut R.} and Krenning, {Eric P.}",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "46",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs

AU - Kwekkeboom, Dik J.

AU - Mueller-Brand, Jan

AU - Paganelli, Giovanni

AU - Anthony, Lowell B.

AU - Pauwels, Stanislas

AU - Kvols, Larry K.

AU - O'Dorisio, Thomas M.

AU - Valkema, Roelf

AU - Bodei, Lisa

AU - Chinol, Marco

AU - Maecke, Helmut R.

AU - Krenning, Eric P.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of radiolabeled somatostatin analogs. Initial studies with high doses of [111In- diethylenetriaminepentaacetic acid (DTPA)0]octreotide in patients with metastasized neuroendocrine tumors were encouraging, although partial remissions were uncommon. Another radiolabeled somatostatin analog that is used for peptide receptor radionuclide therapy (PRRT) is [90Y-1,4,7,10- tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) 0,Tyr3]octreotide. Various phase 1 and phase 2 PRRT trials have been performed with this compound. Despite differences in the protocols used, complete and partial remissions in most of the studies with [ 90Y-DOTA0, Tyr3]octreotide were in the same ranges, 10%-30%; these ranges were higher than those obtained with [ 111In-DTPA0]octreotide. Treatment with the newest radiolabeled somatostatin analog, [177Lu-DOTA0,Tyr 3]octreotate, which has a higher affinity for the subtype 2 somatostatin receptor, resulted in complete or partial remissions in 30% of 76 patients. Tumor regression was positively correlated with a high level of uptake on OctreoScan imaging, a limited hepatic tumor mass, and a high Karnofsky performance score. Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all 111In-, 90Y-, or 177Lu-labeled somatostatin analogs that have been used for PRRT. The results obtained with [ 90Y-DOTA0,Tyr3]-octreotide and [ 177Lu-DOTA0,Tyr3]octreotate are very encouraging in terms of tumor regression. Also, if kidney protective agents are used, the side effects of this therapy are few and mild, and the duration of the therapy response for both radiopharmaceuticals is more than 2 y. These data compare favorably with those for the limited number of alternative treatment approaches.

AB - A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of radiolabeled somatostatin analogs. Initial studies with high doses of [111In- diethylenetriaminepentaacetic acid (DTPA)0]octreotide in patients with metastasized neuroendocrine tumors were encouraging, although partial remissions were uncommon. Another radiolabeled somatostatin analog that is used for peptide receptor radionuclide therapy (PRRT) is [90Y-1,4,7,10- tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) 0,Tyr3]octreotide. Various phase 1 and phase 2 PRRT trials have been performed with this compound. Despite differences in the protocols used, complete and partial remissions in most of the studies with [ 90Y-DOTA0, Tyr3]octreotide were in the same ranges, 10%-30%; these ranges were higher than those obtained with [ 111In-DTPA0]octreotide. Treatment with the newest radiolabeled somatostatin analog, [177Lu-DOTA0,Tyr 3]octreotate, which has a higher affinity for the subtype 2 somatostatin receptor, resulted in complete or partial remissions in 30% of 76 patients. Tumor regression was positively correlated with a high level of uptake on OctreoScan imaging, a limited hepatic tumor mass, and a high Karnofsky performance score. Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all 111In-, 90Y-, or 177Lu-labeled somatostatin analogs that have been used for PRRT. The results obtained with [ 90Y-DOTA0,Tyr3]-octreotide and [ 177Lu-DOTA0,Tyr3]octreotate are very encouraging in terms of tumor regression. Also, if kidney protective agents are used, the side effects of this therapy are few and mild, and the duration of the therapy response for both radiopharmaceuticals is more than 2 y. These data compare favorably with those for the limited number of alternative treatment approaches.

KW - Gastroenteropancreatic tumors

KW - Radionuclide therapy

KW - Somatostatin

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=14844340284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844340284&partnerID=8YFLogxK

M3 - Article

C2 - 15653653

AN - SCOPUS:14844340284

VL - 46

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 1 SUPPL.

ER -